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Abstract
Objectives: Vocal fold (VF) scarring remains a therapeutic challenge. Granulocyte-macrophage colony-stimulating factor
(GM-CSF) facilitates epithelial wound healing, and recently, growth factor therapy has been applied to promote tissue
repair. This study was undertaken to investigate the effect of GM-CSF on VF wound healing in vivo and in vitro.
Methods: VF scarring was induced in New Zealand white rabbits by direct injury. Immediately thereafter, either GM-CSF or
PBS was injected into the VFs of rabbits. Endoscopic, histopathological, immunohistochemical, and biomechanical
evaluations of VFs were performed at 3 months post-injury. Human vocal fold fibroblasts (hVFFs) were cultured with GM-
CSF. Production of type I and III collagen was examined immunocytochemically, and the synthesis of elastin and hyaluronic
acids was evaluated by ELISA. The mRNA levels of genes related to ECM components and ECM production-related growth
factors, such as HGF and TGF-ß1, were examined by real time RT-PCR.
Results: The GM-CSF-treated VFs showed reduced collagen deposition in comparison to the PBS-injected controls (P,0.05).
Immunohistochemical staining revealed lower amounts of type I collagen and fibronectin in the GM-CSF-treated VFs
(P,0.05 and P,0.01, respectively). Viscous and elastic shear moduli of VF samples were significantly lower in the GM-CSF
group than in the PBS-injected group (P,0.001 and P,0.01, respectively). Mucosal waves in the GM-CSF group showed
significant improvement when compared to the PBS group (P= 0.0446). GM-CSF inhibited TGF-b1-induced collagen
synthesis by hVFFs (P,0.05) and the production of hyaluronic acids increased at 72 hours post-treatment (P,0.05). The
expressions of HAS-2, tropoelastin, MMP-1, HGF, and c-Met mRNA were significantly increased by GM-CSF, although at
different time points (P,0.05).
Conclusion: The present study shows that GM-CSF offers therapeutic potential for the remodeling of VF wounds and the
promotion of VF regeneration.
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Introduction
Vocal folds (VFs) are vital for voice production via aerodynam-
ically driven oscillation of pliable, layered VF mucosa. Harmoni-
ous oscillation of VF mucosa, which is important for the
maintenance of voice quality, is mainly attributed to the
biomechanics of the layered structure of VFs. The biomechanical
properties of VF layers are primarily characterized by their
extracellular matrix (ECM) composition and organization [1]. VF
injury caused by vocal abuse, surgery, or inflammation commonly
results in VF scarring, which disrupts the layered structure of VFs,
alters the biomechanical properties of layered VFs, and possibly
leads to intractable dysphonia [2].
A number of recent studies have examined changes in ECM
synthesis and distribution in VFs and found excessive collagen
deposition, low elastin density and disorganization, as well as a low
HA level, in diverse animal VF scar models [3–7]. Regarding the
biomechanics of VFs after scarring, elastic shear modulus and
dynamic viscosity have been reported to be higher for scarred VFs,
and suggested to be due to alterations in ECM composition and
organization [3,6]. Accordingly, the remodeling of ECM compo-
sition and organization by encouraging VF fibroblasts to
synthesize favorable ECM components during the wound healing
phase has been the focus of a number of studies undertaken to
prevent or mitigate scarring.
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Recently, a variety of bioactive factors have been investigated in
regards to their ability to promote VF wound healing. A few
authors have shown that the local administration of growth factors,
including hepatocyte growth factor (HGF) and basic fibroblast
growth factor (bFGF), in injured VFs leads to improved histologic
and biomechanical properties in in vivo animal models [8,9]. Such
growth factors are considered to affect VF fibroblasts during the
wound healing process, enhancing ECM synthesis and deposition
[10]. However, the complex roles played by many growth factors
and cytokines involved in the inflammatory phase of VF wound
healing have not been fully elucidated.
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
is a multipotent cytokine that is synthesized by many cell types,
including macrophages, lymphocytes, fibroblasts, and endothelial
cells, and causes the chemotaxis of inflammatory cells to wound
sites. Additionally, GM-CSF stimulates the proliferation and
differentiation of hematopoietic progenitor cells, increases neovas-
cularization, enhances epithelial regeneration, and plays a
complex tissue-dependent role in fibrosis [11–13]. Recently,
topically applied GM-CSF has been suggested to play an
important role in cutaneous wound repair. A series of animal
experiments and clinical studies have demonstrated a beneficial
effect of GM-CSF for the promotion of wound healing of burns
and chronic ulcers [12,14]. In one of our previous studies,
exogenous GM-CSF was also shown to inhibit glial scar formation
in a spinal cord injury model in rats [15]. However, to date, no
previous study has examined the effect of GM-CSF on VF wound
healing; more specifically, studies of GM-CSF on ECM modula-
tion and tissue repair are scarce.
Taking these studies together, we hypothesized that GM-CSF
would promote wound remodeling following VF injury, and that
the local administration of GM-CSF would improve VF regen-
eration. To prove this hypothesis and to assess the potential of
GM-CSF as a novel therapeutic candidate for VF wound healing,
we investigated the effects of injection of GM-CSF on VF wound
healing in a rabbit model and investigated the mechanisms
involved using in vitro cultured human VF fibroblasts (hVFFs).
Accordingly, functional, macro- and micromorphological evalua-
tions were performed in vivo. For the in vitro model, the primary
outcome measures were morphology, proliferation, and the
production of ECM components, such as collagen, elastin, and
hyaluronic acid (HA). In addition, we assessed the expressions of
genes related to ECM components and ECM production-related
growth factors, such as HGF and TGF-ß1.
Materials and Methods
Ethics statement
This study was approved by the Animal Ethics Committee of
The Inha University Hospital (Permit Number: 111031-114), and
animal care was strictly provided according to established
institutional guidelines. All surgery was performed under anesthe-
sia by premedication with xylazine (5 mg/kg) and an intramus-
cular injection of 15 mg/kg of zolazepam, making every effort to
minimize suffering.
Animal experiments
Selection of an animal model depends on the structural
characteristics of the animal’s VFs, as well as other practical
considerations. Rabbit models have been widely used in VF scar
research because of an appropriate VF size for function
measurement, as well as due to similarities in the layered structure
and ECM components of rabbit VFs with human VFs [16]. For
the experiments, 30 New Zealand white rabbits weighing 3.1–
3.6 kg were used. The animals were randomly divided into three
groups of 10 rabbits: an uninjured group (normal), an injured and
phosphate-buffered saline (PBS) treated group (scar control), and
an injured and GM-CSF treated group (experimental group). The
animals were pre-medicated subcutaneously with 0.05 mg/kg of
glycopyrrolate and then anesthetized. The larynx was visualized
using a pediatric laryngoscope (Karl Storz, Tuttlingen, Germany)
and a surgical operating microscope (Carl Zeiss Ltd, Welwyn
Garden City, UK). Unilateral VF injury was induced in six
animals from each group as previously described; the method
involved excising VF epithelium and lamina propria using a sickle
knife and microcup forceps [17]. Contralateral VFs were used as a
control. Bilateral VF injuries were administered in four animals of
each group for rheological evaluation.
Immediately after injury, 50 mL of rhGM-CSF (1 mg/mL in
saline) was directly administrated into VFs in the experimental
group. In the scar control group, 50 mL of PBS was injected. A
Hamilton syringe with a 25 G needle was used to inject PBS or
GM-CSF to VFs under direct vision using a pediatric laryngo-
scope and surgical operating microscope.
In vivo assessment
Macroscopic evaluation and high speed digital
imaging. At 1 and 3 months post-injury, an endoscopic
evaluation was performed in all three groups and scar formation
on VFs was assessed macroscopically. Two larynges were then
excised post-euthanasia for ex vivo evaluation of the mucosal wave.
Briefly, the larynx was mounted on a table, through which airflow
was passed from an airflow generator below the table to the larynx
to generate vocal fold vibrations. All supraglottic structures were
removed for better visualization and VFs were closed by suturing
the vocal processes of arytenoid cartilages. Symmetry was
maintained across the mid sagittal plane using arytenoid
micromanipulators, such that both VFs were aligned. Expiratory
airflow was artificially generated by allowing a certain volume of
room air to flow constantly. Mucosal waves were recorded using a
High speed digital imaging system (MegaSpeed HHCX6, Cana-
dian Photonic Labs INC, Minnedosa, CA) in gray scale at an
image size of 5126512 pixels. Images of duration with 0.2 seconds
were captured at 5000 frames per second (fps). A single line in
mid-coronal glottal plane from high speed digital images was
selected to produce kymographs. The amplitudes of mucosal
waves were evaluated by measuring the pixels of oscillation of VF
upper lips between the open phase and closed phase on
kymographs using image analysis software (Metamorph, Molecu-
lar Devices Corporation, Sunnyvale, CA), and were normalized
relative to those of contralateral normal VF. During the
examination, VFs were maintained wet by dripping saline solution
at 37uC
Functional rheometric evaluation. Three months post-
injury, four larynges in each group were removed post-euthanasia.
VFs without muscles and other supra- and subglottic connective
tissues were meticulously dissected under magnified vision using a
surgical operating microscope. Each VF sample was approximate-
ly 5 to 6 mm in length and 2 to 3 mm in depth. The eight
dissected VFs were stored in normal saline at 37uC for a couple of
hours until viscoelastic measurements were undertaken.
A strain-controlled rheometer (ARES-LS, TA Instruments, New
Castle, Delaware, USA) was used to measure the viscoelasticity of
the dissected VFs. A sample was placed between the 2 parallel
plates of the rheometer. The rotating lower plate included a
temperature control system and a steady or oscillatory shear
deformation upon the samples. A piezoelectric force transducer of
the upper plate with measurement geometry recorded the shear
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stresses resulting from steady or oscillatory shear deformation. The
diameter of the upper plate used for VF tissue samples was 3 mm,
and inter-plate gap size was at 0.8–1.2 mm to allow full contact
between samples and the upper plate. The temperature of the
lower plate was set at 37uC, and samples were maintained in a
humidified environment (RH 100%).
A dynamic frequency sweep test at frequencies ranging from 0.1
to 100 rad/s was used to apply oscillatory shear deformation to the
samples. Sample linear viscoelastic conditions were measured
using a series of dynamic strain sweep tests prior to frequency
sweep testing. TA Orchestrator software (ARES-LS, TA Instru-
ments, New Castle, Delaware, USA) was used to calculate shear
stresses, shear strains, and shear strain rates. Viscoelastic
parameters, such as elastic modulus (G9) and viscous modulus
(G0), were calculated as functions of applied frequency according to
the theory of linear viscoelasticity. Dependence of viscoelastic
parameters on frequency can be parameterized by the power law,
in which the coefficient ‘a’ indicates magnitude and the constant
‘b’ indicates slope on a log-log scale.
Histopathological and immunohistochemical
examination. Four larynges in each group were harvested for
histological analysis post-euthanasia at 3 months post-injury.
Specimens were embedded in paraffin blocks and embedded tissue
samples were sectioned at 4 mm using a microtome along the
coronal axis of the larynx and stained with; hematoxylin and eosin
(H-E), Masson’s trichrome (for collagen), Verhoeff’s van Gieson
(for elastic fibers), or alcian blue (for total glycosaminoglycans)
using standard pathology department protocols.
For immunohistochemical examinations of collagen type I and
fibronectin, paraffin sections of excised larynges were deparaffi-
nized in xylene, rehydrated in ethanol, and washed with PBS.
Thereafter, nonspecific binding was blocked with a blocking
solution containing 1% bovine serum albumin. Slides were
incubated overnight at 4uC with a primary antibody against
collagen type I (1:100 dilution, AB Biotec) and fibronectin (1:50
dilution, Abcam). Secondary Alexa fluor 555-conjugated anti-
mouse IgG antibodies (1:500 dilutions, Cell Signaling) were then
applied to the slides for 1 hour in the dark at room temperature,
followed by 49,6-diamidino-2-phenylindole dihydrochloride
(DAPI; Vector Labs, H-1500) treatment for 3–5 minutes to stain
cell nuclei. All experiments included a slide not treated with
primary antibody as a negative control. Three sections were
prepared for each VF, and 12 slides in total were analyzed using a
confocal laser-scanning microscope. A blinded examiner measured
the ECM contents by calculating pixel areas using MetaMorph
software (Molecular Devices Corporation, Sunnyvale, CA, USA).
Immortalized hVFF cell lines
The immortalized hVFF cell lines (cell line #A8P3) were kindly
provided by Susan L. Thibeault at the University of Wisconsin.
Full immortalization details and characterization of this cell line
are described elsewhere [18]. Immortalized hVFFs showed similar
morphological features and ECM gene expressions beyond
passage 25. For this experiment, hVFFs obtained between the
5th and 6th passages were used.
In vitro assessments
Cell morphology and proliferation assay. The morphol-
ogy of hVFFs was observed using phase contrast microscopy. Cell
proliferation was assessed in triplicate using a Cell Counting Kit-8
(CCK-8; Dojindo, Gaithersburg, MD), according to the manu-
facturer’s instructions. Aliquots of hVFF cells (100 mL/36103 cells)
cultured in 96-well plates were serum-starved overnight and then
treated with serum-free medium containing 0, 10, 100, or 500 ng/
mL of GM-CSF for 12, 24, or 72 hours. The CCK-8 reagent
(10 mL) was then added to each well 1 h before completing the
incubation. Absorbance at 450 nm was measured using a
microplate reader.
Biochemical analyses. The production of insoluble elastin
was quantified biochemically. Elastin amounts in hVFFs were
measured using a Fastin elastin assay kit (Biocolor Ltd,
Carrickfergus, UK). Since the Fastin assay quantified only soluble
a-elastin, all samples were converted from the native hydrophobic
elastin into a water soluble derivative. To extract a-elastin,
samples were heated at 100uC for 1 h period with 0.25 M oxalic
acid. Solubilized proteins containing elastin extract were precip-
itated overnight by adding Fastin precipitating reagent. Collected
pellets (12,000 rpm for 10 min) were mixed with Fastin dye
reagent, which contained 5,10,15,20-tetraphenyl-21H, 23H-pro-
pine tetrasulfonate (TPPS) in a citrate-phosphate buffer for
90 min. The elastin-dye complex obtained was precipitated
(12,000 rpm for 10 min), mixed with dye dissociation reagent for
10 min, and absorbance of the recovered dye, a-elastin standards,
and blanks were measured at 513 nm using a microplate reader.
Quantitation of HA levels in culture media was performed using
an enzyme-linked immuno assay (ELISA). HA in media was
measured in triplicate using an ELISA kit (Echelon Biosciences,
Salt Lake City, UT, USA). Briefly, the HA detector was mixed
with HA standard and culture media and incubated for 1 hour at
37uC, after which samples were transferred to a detection plate.
After incubation for 30 min at 4uC working enzyme was added to
the detection plate and samples were incubated in the dark at
room temperature. Finally, absorbance was measured at 405 nm.
Immunocytochemical analyses. The synthesis of types I
and III collagen from the hVFFs was stimulated by TGF-ß1 and
then analyzed by immunocytochemical staining. Briefly, near-
confluent hVFFs were serum-starved overnight and treated with
10 ng/mL of TGF-ß1 with or without 500 ng/mL of GM-CSF for
5 days. Cultured hVFFs were then washed with PBS, fixed in 4%
paraformaldehyde (PFA) for 15 min, and permeabilized in PBS
containing 0.2% Triton X-100 (Sigma-Aldrich, St. Louis, MO,
USA) for 10 min. Nonspecific binding was blocked in a blocking
solution containing 2% bovine serum albumin, and slides were
incubated with primary antibody against type I or III collagen
(1:100 dilution, AB Biotec, San Diego, CA, USA) overnight at
4uC. Secondary Alexa fluor 488-conjugated anti-rabbit IgG
antibodies (1:500 dilutions, Invitrogen, Carlsbad, CA, USA) were
then applied to the slides for 1 hour in the dark at room
temperature, and 49,6-diamidino-2-phenylindole, dihydrochloride
(DAPI; Vector Labs, H-1500) was applied for 3–5 min to stain cell
nuclei. All experiments included a slide not treated with primary
antibody as a negative control. Slides were analyzed using laser-
scanning confocal microscopy (Olympus FV1000, Japan) at a
magnification of 6400. Type I and III collagen production was
measured by calculating pixels in areas of positive staining using
MetaMorph software.
Transcriptional evaluation. Total RNA was harvested
from hVFF cells using Trizol (Invitrogen, Carlsbad, CA) according
to the manufacturer’s directions. Total RNA concentrations were
measured spectrophotometrically, and RNA amounts were
assessed by gel electrophoresis. One microgram of total RNA
was transcribed into complementary DNA using a Prime-
ScriptTM RT reagent kit (Takara, Japan). Real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) was carried
out in 20 ml of reagents (SYBR Premix Ex TaqTM II, Takara
#RR081A) containing cDNA (1 ml) and the specific primers for
each gene (detailed in Table 1). RT-PCR was performed using the
StepOnePlus Real-Time PCR system (Applied Biosystems, Foster
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City, CA) over 40 cycles of; denaturation at 95uC for 10 sec,
annealing at 55uC for 25 sec, and extension at 72uC for 30 sec.
After amplification, reaction efficiencies were determined using
melting curves constructed from purified PCR products and
mRNA levels in tissue samples were quantified. Negative controls
containing water instead of template and initial mRNA were
included in each run to rule out the contamination of DNA and
genomic DNA. The housekeeping gene of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal
control. Relative gene expressions (fold-changes) were calculated
using the 2-DDCT method.
Statistics
All statistical analyses were conducted using the Graph Pad
Prism 5 package (GraphPad Software Inc., La Jolla, CA). The
Mann-Whitney test was used to determine the significances of
differences between two groups, and the Kruskal-Wallis followed
by the Dunns’ post hoc test was used to compare values of the
three groups. Rheological data were analyzed using the two-way
ANOVA by post hoc test (Bonferroni test). Statistical significance
was accepted for p values,0.05.
Results
Macroscopic and functional evaluation
Macroscopic evaluations were performed at 1 and 3 months
post-VF injury. Endoscopic findings revealed that fibrotic scarring
was not prominent in GM-CSF-treated VFs, whereas scar bands
remained prominent at 3 months post-injury in PBS-treated
control VFs (Fig. 1).
For functional evaluations, the amplitudes of VF mucosal waves
were measured by kymography from high-speed digital images
(Fig. 2A). The ratio of the amplitudes of mucosal waves of injured
right VFs versus normal contralateral VFs were significantly
higher in the GM-CSF group than in the PBS group (P=0.0446,
Fig. 2B).
Viscoelastic properties of VFs were plotted on a log-log scale as
a function of the frequency (Fig. 3). The PBS group had
significantly higher G9 and G0 values than the non-injured control
group (P,0.001 or both of G9 and G0) and the GM-CSF group
(P,0.001 and P,0.01, respectively), indicating that GM-CSF
treated VFs were more fluidic and less stiff than PBS treated VFs.
Relations between the viscoelastic properties and frequency were
described by G9 or G0= axb, where ‘a’ was equal to the magnitude
and ‘b’ the slope on the log-log scale. Curve fitting results are
shown in Table 2.
Histopathology and immunohistochemistry
H-E staining and Masson’s trichrome staining showed that GM-
CSF treatment exerted favorable effects. GM-CSF reduced
collagen deposition (Fig. 4). Verhoeff’s staining revealed that
elastic fibers in the GM-CSF group tended to be less disorganized
and less tangled. Alcian blue staining revealed that VFs in the
GM-CSF group tended to exhibit higher glycosaminoglycan levels
than VFs in the PBS group.
Immunohistochemical analysis demonstrated that the deposi-
tion of type I collagen and fibronectin was lower in GM-CSF-
treated VFs than in PBS-treated VFs (Fig. 5). These results were
further confirmed by densitometric analysis using MetaMorph
software (Figs. 6A,6E).
Effects of GM-CSF on the hVFF morphology and
proliferation
hVFFs cultured in serum-free medium exhibited typical spindle-
like fibroblast morphology, and showed no significant change in
morphology when treated with different dosages (10–500 ng/mL)
of GM-CSF over 72 hours (Fig. 7A). Proliferation of hVFFs in
response to different doses of GM-CSF was assessed using the Cell
Table 1. Primer sequences used for real time PCR.
Genes Forward primer sequences Reverse primer sequences
HA synthease-2 59-GGGGGAGATGTCCAGATTTT-39 59-ATGCACTGAACACACCCAAA-39
TGF-b1 59-ACAATTCCTGGCGATACCTCA-39 59-GGCGAAAGCCCTCAATTTC-39
Fibronectin 59-CAATCCAGAGGAACAAGCATGTCTC-39 59-GCTTTCCTATTGATCCCAAACCAAA-39
Tropoelastin 59-CGAACTTTGCTGCTGCTTTAG-39 59-GTGTATACCCAGGTGGCGTG-39
HGF 59-CCTAGATCTTTCCAGTTAATCACACAAC-39 59-TTCGGAGTCAGTGCCTAAAAGAG-39
c-Met 59-TTAAAGGAGACCTCACCATGTAATC-39 59-CCTGATCGAGAAACCACAACCT-39
MMP-1 59-GGGAGATCATCGGGACAACTC-39 59-GGGCCTGGTTGAAAAGCA-39
MMP-2 59-TTCCTGGGCAACAAATATGAGA-39 59-TGGTCGCACACCACATCTTT-39
Collagen I 59-CAGCCGCTTCACCTACAGC-39 59- TTTTGTATTCAATCACTGTCTTGCC-39
Collagen III 59- ACACGTTTGGTTTGGAGAGTCC-39 59-CTGCACATCAACGACATCTTCAG -39
GAPDH 59-ATGGGGAAGGTGAAGGTCG-39 59-TAAAAGCAGCCCTGGTGACC-39
doi:10.1371/journal.pone.0054256.t001
Figure 1. Macroscopic findings of scarred VFs at 3 months after
PBS or GM-CSF treatment. Morphological improvement was
observed in (B) GM-CSF treated VFs, which showed smaller fibrotic
bands (arrow). In contrast, scar bands (arrow) remained prominent in (A)
PBS-treated control VFs.
doi:10.1371/journal.pone.0054256.g001
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Counting Kit-8 (CCK-8) and showed no significant changes over
time (Fig. 7B).
ECM production by hVFFs after GM-CSF treatment
In order to assess ECM production in response to GM-CSF
treatment, we first measured TGF-ß1-induced type I and III
collagen accumulation in hVFFs after 72 hrs of treatment. TGF-
ß1 is known to be involved during acute inflammation and
neomatrix deposition following VF injury; moreover, exogenous
TGF-ß1 has been shown to increase collagen secretion from
hVFFs [19]. Immunocytochemistry revealed that GM-CSF did
not affect type I and type III collagen (both P.0.05, Fig. 8)
production by itself, but significantly reduced TGF-ß1-induced
accumulation of type I collagen, but not type III (P,0.05, Figs. 8A
and 8B).
Subsequently, the effect of GM-CSF on the production of
elastin in hVFFs and secretion of HA to the culture media was
examined. The elastin content was not significantly different upon
GM-CSF treatment at all concentrations and time-points tested
(P.0.05, Fig. 9A). HA levels were significantly greater in culture
media only when GM-CSF was treated at 500 ng/mL for
72 hours (P,0.05, Fig. 9B).
Gene expression after GM-CSF treatment
To gain further insight into the mechanism of ECM production
by GM-CSF, the expressions of genes related to ECM components
and ECM production-related growth factors, such as HGF and
TGF-ß1, were examined.
HAS-2 expression was significantly elevated at 12 and 24 hours
upon treatment with 100 and 500 ng/mL of GM-CSF (P,0.001),
and this increase was maintained up to 72 hours upon treatment
Figure 2. Kymographs from high-speed digital images. (A) The amplitudes of mucosal waves (MW) of VFs were measured in triplicate by
measuring the pixels of oscillation of upper lips between the open phase and closed phase on high-speed digital images using image analysis
software. (B) The amplitude ratio of MWs in injured right VFs relative to normal contralateral VFs was measured quantitatively. The normalized MW
was significantly greater in the GM-CSF group than in the PBS group (n = 6, P= 0.0446).
doi:10.1371/journal.pone.0054256.g002
Figure 3. Functional rheometric evaluation at 3 months after injury: mean elastic moduli (G9 ) and viscous moduli (G0 ) were plotted
on a log-log scale as a function of frequency. (A) The G9 values of VF samples were significantly lower in the GM-CSF group (m) than in the
injured PBS group (X) (n = 8, P,0.001). (B) The G0 values of tissue samples were also significantly lower in the GM-CSF group (m) than in the PBS
treated group (X) (n = 8, P,0.01). Both of the values in the GM-CSF group were quite a similar to those of normal VF samples (#).
doi:10.1371/journal.pone.0054256.g003
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Table 2. Results of curve fitting by the power law of the plots between mean elastic modulus (G9) and mean viscous modulus (G0)
and applied frequencies for tissue samples of VFs.
G9=axb a (PaNs) b R2
Normal 235.07637 0.123 0.752
PBS 415.826157.3 0.111 0.883
GM-CSF 265.13692.83 0.118 0.823
G0= axb
Normal 94.83669.24 0.125 0.51
PBS 156.61667.78 0.122 0.817
GM-CSF 102.94632.74 0.08 0.508
doi:10.1371/journal.pone.0054256.t002
Figure 4. Histopathology of VFs at 3 months post-injury in the PBS and GM-CSF groups. H-E and Masson’s trichrome staining showed less
collagen deposition in GM-CSF-treated VFs. Verhoeff’s van Gieson staining showed less disorganized and less tangled elastin in the GM-CSF-treated
VFs, and VFs in the GM-CSF group appeared to be richer in glycosaminoglycans in the alcian blue staining. Scale bar = 50 mm in 200X, 100 mm in
400X.
doi:10.1371/journal.pone.0054256.g004
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with 500 ng/mL of GM-CSF (P,0.01, Fig. 10A). Tropoelastin
expression was up-regulated dose-dependently by GM-CSF at
12 hours, but decreased significantly thereafter with the GM-CSF,
demonstrating a negligible and varying effect (P,0.01, Fig. 10B).
Furthermore, GM-CSF elicited the induction of MMP-1 at 12 and
24 hours (P,0.01), which was greatly reduced but sustained at
72 hours by treatment with 500 ng/mL of GM-CSF (P,0.001,
Fig. 10C). The mRNA level of MMP-2 was significantly increased
by treatment with 100 ng/mL of GM-CSF at 72 hours (P,0.01,
Fig. 10D). GM-CSF also significantly up-regulated mRNA levels
of HGF and c-Met at 12 hours in a dose-dependent manner, but
that of HGF was only maintained high by GM-CSF at 24 and
72 hrs (P,0.001, Figs. 10G and 10H). In contrast, GM-CSF did
not significantly affect the expression of fibronectin or TGF-ß1 at
any time point (Figs. 10E and 10F). Transcriptional analyses of the
expressions of type I and type III collagen mRNA were conducted
after treating hVFFs with 10 ng/mL of TGF-ß1 with or without
GM-CSF (10, 100 and 500 ng/mL) for 3 days. Compared with
the TGF-ß1 treatment alone, co-treatment of TGF-ß1 and GM-
CSF did not reduce the mRNA levels of type I or type III collagen
(data not shown).
Discussion
Wound healing is a complex process that is controlled by many
growth factors and cytokines. Furthermore, multiple biological
pathways are known to be activated and involved in synchronizing
responses after tissue injury [20–22]. However, wound repair
commonly leads to fibrotic healing, which results in scar formation
rather than tissue regeneration, and thus, many studies have been
undertaken to redirect fibrotic healing processes toward regener-
ative healing by modulating specific pathways.
The process of fibrotic wound healing is known to be cell- and
microenvironment-specific. VF scars are common and usually
even a small lesion in VF epithelium can have a significant effect
on voice production. Some studies have reported that the
expressions of several inflammatory cytokines and growth factors
change in-line with changes in ECM production following VF
injury in vivo [23–27]. Furthermore, others have suggested possible
target cytokine pathways, such as interleukin-1 ß (IL-1ß), tumor
necrosis factor-a (TNF-a), and prostaglandin E2 (PGE2), as
candidates for the mitigation of fibrotic scar formation [28–30].
Figure 5. Immunohistochemical staining of type I collagen and fibronectin in the VFs of GM-CSF and PBS groups at 3 months post-
injury. Immunohistochemical analysis of VFs demonstrated that the type I collagen and fibronectin levels, shown in the green fluorescence, were
lower in the GM-CSF-treated VFs than in the PBS-treated VFs. Scale bar = 50 mm.
doi:10.1371/journal.pone.0054256.g005
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However, the events following VF injury have only partially been
elucidated.
The present study demonstrated that GM-CSF administration
can promote VF regeneration by wound remodeling following
injury, and improve the functional properties of VFs, i.e.
biomechanical aspects such as viscoelastic properties and mucosal
waves. We speculate that these results were related to in vivo
findings, namely reduced depositions of type I collagen and
fibronectin, less disorganized elastin, and increased HA synthesis,
in comparison to PBS treated controls. In our in vitro study, we
found that GM-CSF rescued excessive collagen production and
increased HA synthesis, possibly via collagen degradation due to
MMP-1 activation and via HAS up-regulation.
No consensus has been reached regarding the relation between
GM-CSF and fibrosis. In one study, exogenous GM-CSF
administration was found to inhibit fibrosis in human in vivo study
and to down-regulate collagen production selectively in wound
fibroblasts in vitro [31]. However, in another study, no effect was
Figure 6. Densitometry findings for ECM contents in regenerated VFs. The histochemical or immunohistochemical images were used to
quantitate positive areas of collagen (blue in Masson’s trichrome staining), elastin (black in Verhoeff’s van Gieson staining), glycosaminoglycans (blue
in Alcian blue staining), type I collagen and fibronectin. (A) Collagen deposition showed a reduction in GM-CSF group compared with the PBS group
(B) The VFs in the GM-CSF group tended to exhibit less disorganized and tangled elastin compared with PBS group. (C) Alcian blue staining of VFs
tended to reveal higher glycosaminoglycan levels in the GM-CSF group than in the PBS group. (D) Type I collagen deposition was significantly lower
in the GM-CSF-treated VFs than the PBS group. (E) Quantitative analysis of fibronectin-positive areas revealed significantly less positivity in the GM-
CSF-treated group than the PBS group (n = 12, *P,0.05 and **P,0.01).
doi:10.1371/journal.pone.0054256.g006
Figure 7. Effects of GM-CSF treatment on hVFF morphology and proliferation. (A) Phase contrast microscope images of hVFFs cultured
with GM-CSF (0, 10, 100, 500 ng/mL) for 72 h. Scale bar = 200 mm. (B) Cell proliferation was measured after GM-CSF treatment at 12, 24, and 72 hrs
using a CCK-8 assay. GM-CSF did not significantly alter hVFF morphology or proliferation.
doi:10.1371/journal.pone.0054256.g007
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Figure 8. TGF-ß1-induced collagen production in hVFFs after GM-CSF treatment. (A and B) Immunocytochemistry for type I collagen
revealed that GM-CSF itself did not affect the production of type I collagen in hVFFs at 72 hours after treatment. However, the TGF-ß1-induced
synthesis of type I collagen significantly decreased by GM-CSF treatment (*P,0.05 and **P,0.01). (C and D) GM-CSF did not affect the production of
type III collagen in hVFFs, regardless of TGF- ß1 treatment (P.0.05). All experiments were carried out in triplicate.
doi:10.1371/journal.pone.0054256.g008
Figure 9. Biochemical analyses of elastin and HA synthesis in hVFFs after GM-CSF treatment. (A) The production of elastin in hVFFs was
not found to be significantly dependent on GM-CSF concentration or treatment time (P.0.05). (B) HA levels significantly increased after 72 hours of
GM-CSF treatment only at 500 ng/mL (*P,0.05). All experiments were performed in triplicate.
doi:10.1371/journal.pone.0054256.g009
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Figure 10. Real time PCR of gene expression in hVFFs after GM-CSF treatment. hVFFs were treated with 0, 10, 100 and 500 ng/mL of GM-
CSF for 12, 24, and 72 hours. Real-time PCR showed that GM-CSF treatment increased the expression of HAS-2, tropoelastin, HGF, c-Met, and MMP-1
at different time points. All experiments were carried out in triplicate. Results were normalized versus mRNA levels of GAPDH. *P,0.05, **P,0.01, and
***P,0.001.
doi:10.1371/journal.pone.0054256.g010
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noted following systemic injection of GM-CSF [32]. In the present
study, in vivo collagen deposition was found to be reduced after
GM-CSF treatment, but type I collagen mRNA expression was
not reduced when hVFFs were in the presence of TGF-ß1 in vitro.
Thus, fewer fibrotic changes in GM-CSF-treated VFs than in
PBS-treated VFs could be attributed to collagen degradation by
MMP-1 or the attenuating effect of HAS-2 on collagen synthesis in
hVFFs. Accordingly, we are of the opinion that GM-CSF plays a
complex role in the fibrotic process depending upon the
circumstances.
HA is a non-sulfated glycosaminoglycan and exhibits extensive
molecular interactions that cause it to remain entangled and
hydrated in the ECM, and interestingly, HA has been reported to
play an important role in determining the viscoelastic properties of
VFs [33]. In this study, GM-CSF-treated hVFFs exhibited
elevated HA levels, possibly due to HAS elevation. However, it
remains to be determined whether treatment of hVFFs with GM-
CSF alone elevates HAS-2 expression and whether this up-
regulation or the secondary stimulation of HGF induces HA
synthesis. The administration of GM-CSF did not appear to
regulate elastin synthesis directly, although in vivo histologic
examinations exhibited less elastin disorganization and fragmen-
tation in scarred VFs.
GM-CSF reportedly stimulates wound repair both directly and
indirectly via induction of secondary cytokines [34,35]. In addition
to the primary chemotactic effects of GM-CSF on neutrophils and
macrophages that lead to inflammatory response and the
promotion of wound repair, GM-CSF has been observed to cause
endothelial cells and fibroblasts to secrete other growth factors in
an autocrine or paracrine fashion.
In this study, GM-CSF up-regulated HGF and its membrane-
spanning tyrosine kinase receptor, c-Met, but did not regulate
TGF- ß1 expression. The growth factors, HGF and TGF-ß1, have
been shown to play different roles in the stimulation and inhibition
of ECM production by hVFFs. HGF favors HA up-regulation and
collagen down-regulation, whereas TGF-ß1 increases the produc-
tion of type I collagen and fibronectin, which plays a major
etiologic role in chronic fibrosis [27]. Thus, alterations in the
balance between HGF and TGF-ß1 are likely to cause suboptimal
wound healing. HGF activity was reported to peak by day 10
following VF injury in a rabbit model [26]. In our study, HGF
expression was significantly increased at 12 hours and was
maintained at a high level at 24 and 72 hours by GM-CSF.
Thus, we assumed that the indirect actions of HGF, induced more
rapidly by exogenous GM-CSF, likely promoted the wound
healing process in our model.
Our in vitro study has some limitations. First, hVFFs were not in
their native physiologic environment and in vitro data cannot
represent the complex interactions that exist between multiple cell
types, matrices, and mediators at the sites of injury. Second, it is
difficult to draw conclusions regarding optimal dosages and
appropriate times of administration due to the variability of
expression data obtained at particular time points following GM-
CSF treatment. Although in vivo animal models may concur with in
vitro data and provide biological insights of the functions of
different mediators, we suggest that a transgenic and knock-out
mouse model should be developed for future wound healing
experiments.
Conclusion
The results of the present study suggested that GM-CSF plays a
role in wound remodeling following VF injury, and that GM-CSF
either directly or indirectly exerts favorable effects such as the
rescue of excessive collagen deposition and an increase in HA
synthesis. Finally, our findings suggest that GM-CSF should be
viewed as a potential therapeutic candidate for the prevention of
VF scarring and the promotion of VF regeneration.
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